SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Staff Says Genentech, Inc.'s Avastin Brain Cancer Data Unclear

March 30, 2009 | 
1 min read
WASHINGTON, March 27 (Reuters) - It is difficult to tell how well brain cancer patients responded to Genentech Inc's cancer drug Avastin in early studies from the company, U.S. Food and Drug Administration staff said in documents released on Friday.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach
screenshot of Marty Makary speaking on the Megyn Kelly Show
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of man walking in the beach between two blue seas, surreal abstract path concept
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
 · 
3 min read
 · 
Nick Paul Taylor